Lived experiences of patients receiving maintenance therapy with PARP inhibitors for advanced ovarian cancer

Objective: Advanced ovarian cancer is often diagnosed at stages IIIB–IV, with frequent recurrence and poor prognosis despite standard treatment. Poly(ADP-ribose) polymerase (PARP) inhibitors are available as maintenance therapies; nonetheless, evidence on patient experiences remains limited. This study clarified patient experiences during maintenance therapy with PARP inhibitors and identified nursing support implications.
Methods: We used a descriptive qualitative design. Three women with advanced ovarian cancer (40s–70s; FIGO stage IIIB–IIIC; two with recurrence) attending an outpatient clinic were recruited. Semi-structured interviews were conducted up to five times within 6 months after therapy initiation (total, 531 min), and medical records were reviewed. Transcripts were analyzed using the KJ method.
Results: Seven categories were identified. Patients described PARP inhibitors as “a talisman-like treatment” that provided reassurance and enabled them to navigate daily life despite concerns about heredity and financial burden; they valued “the support of family, colleagues, and healthcare providers” and wished “to live by trusting in PARP inhibitors even under uncertainty.” They reported “symptom observation and daily management” as self-care strategies and expressed “fear of cancer and harsh treatments,” “conflicts in regaining self-identity,” and a strong need “for a place to consult about symptoms, costs, and continuation of therapy.”
Conclusions: Patients balanced reassurance and uncertainty, supported by treatment efficacy and social relationships, but challenged by fear, financial strain, and identity loss. Nurses should assess these experiences and provide individualized consultations addressing symptoms, economic concerns, and genetic issues. Early, continuous consultation and strengthened multidisciplinary collaboration are essential to sustain treatment and improve quality of life.